April 8, 2019 | Nancy Tyrrell
CBC Accelerator Network (CBCAN) meeting: Accelerator Award proposals Round Three, Part One
Round 3 of the CBC’s Accelerator Award program began accepting Letters of Intent on January 14, 2019 for the funding award of up to $250,000 for a two year period. Nine finalists with promising therapeutic and/or an associated diagnostic or biomarker proposals have advanced and continue forward. An important step in the application process includes a live presentation of the finalists’ programs and supporting data at a CBCAN event.
The first of two CBCAN meetings took place on Thursday, March 28 at Northwestern Memorial Hospital’s Feinberg Pavilion. The presenters and their programs included William Muller, Northwestern University, “A first-in-class anti-inflammatory agent to block ischemia/ reperfusion injury”, Jeffrey Loeb, University of Illinois at Chicago, “Non-invasive MR spectroscopic method to image the human epileptic brain”, Sui Huang, Northwestern University, “Chemical improvement of metarrestin, an effective anti-metastic lead”, and C. David James and Jack Henkin, Northwestern University, “Optimized combination chemotherapy of glioma with PEDF-derived peptide NU-335”.
Each Principal Investigator delivered an eight-minute presentation which summarized novel approaches for their areas of research. The presenters addressed unmet medical needs and commercial implications, key supportive data, competitive landscape, specific aims, challenging risks, and proposed next steps for their programs. Following the presentations, the audience provided verbal and written feedback for the investigators to consider when submitting their full proposal applications.
During the March 28th CBCAN program, we also had the opportunity to introduce our newest member of the CBC, Molly Reese, Executive Assistant to Jim Audia. Welcome, Molly!
Once the live presentations wrapped up, the audience and presenters proceeded to the community networking reception to continue the conversation over hors d’oeuvres and drinks.
We look forward to Part Two of the Accelerator Award presentations at Women’s Prentice Hospital on Tuesday April 16.
Please join us in welcoming five additional finalists as they present their translational research, including Peng Ji, Northwestern University, “Antithrombotic therapy using PLEK2 inhibitors”, Steve Ackerman and Vadim Gaponenko, University of Illinois at Chicago, “Novel CCR3 peptide biased antagonist for therapy of eosinophilic asthma and eosinophilic esophagitis”, Karla Satchell, Northwestern University, “RAS processing as a strategy to reduce RAS-driven tumors”, Brian Kay, University of Illinois at Chicago, “Best-in-class affinity reagents to Kras”, and Gye Young Park and Michael Johnson, University of Illinois at Chicago, “Inhaled colony stimulating factor 1 receptor inhibitor for asthma therapy”.
Enjoy the photo-gallery of the March 28th CBCAN event!
▸ CBCAN Program, March 28, 2019